Up to $100,000,000 Common Shares

This prospectus supplement updates and amends certain information contained in the prospectus supplement dated July 19, 2023, to the prospectus dated July 19, 2023 (collectively, the “July 2023 Prospectus”) relating to the offer and sale of shares of our common stock through or to B. Riley Securities, Inc. (“B. Riley Securities”) and Cantor Fitzgerald & Co. (“Cantor” and together with B. Riley Securities, the “Agents”) as co-agents or principals, in “at the market offerings” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, pursuant to the Amended and Restated Sales Agreement with the Agents dated as of June 7, 2021, as amended on December 17, 2021 and July 19, 2023 (the “Sales Agreement”).

This prospectus supplement should be read in conjunction with the July 2023 Prospectus and is qualified by reference to the July 2023 Prospectus, except to the extent that the information presented herein supersedes the information contained in the July 2023 Prospectus. This prospectus supplement is not complete without, and may only be delivered or used in connection with, the July 2023 Prospectus, including any amendments or supplements thereto.

Our common shares are listed on the NYSE American (“NYSE American”) under the symbol “URG” and on the Toronto Stock Exchange (“TSX”) under the symbol “URE.” On June 17, 2024, the closing price of our common shares on the NYSE American was $1.45 and on the TSX was CDN$1.99.

Under the July 2023 Prospectus, we initially registered up to $50,000,000 of our common shares, no par value per share, for offer and sale pursuant to the Sales Agreement, not inclusive of amounts previously sold. From July 19, 2023 through June 17, 2024, we sold an aggregate of 19,317,281 common shares for an aggregate gross purchase price of $32,737,728.70 under the July 2023 Prospectus. As of the date of this prospectus supplement, we are increasing the amount of common shares that we are offering pursuant to the Sales Agreement by $50,000,000, such that we are offering up to an aggregate of $100,000,000 of our common shares for sale under the Sales Agreement from and after the date hereof, including the common shares previously sold.

Investing in our common shares involves significant risks. Before buying common shares, you should carefully consider the risks described under the caption “Risk Factors” in the documents incorporated by reference into this prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is June 18, 2024.